Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy
Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy
Actual clinical practice predominantly makes use of heparin (systemically) or citrate
 regionally as anticoagulation in the extracorporeal circulation for renal replacement
 therapy. We aim to find out if different anticoagulation strategies may lead to different
 levels of platelet activation and whole blood coagulation. Regarding coagulation activation,
 it remains uncertain if there is an advantage for one of these methods. However, it is of
 major interest to minimize the risk of any additional clotting activation via extracorporeal
 circulation in these usually critically ill patients.
Inclusion Criteria:

 -  Age > 18 years, acute renal failure with need for continuous veno-venous renal
 replacement therapy

 Exclusion Criteria:

 -  Age < 18 years, pregnancy, contraindications for one of the two anticoagulation
 methods, missing informed consent or disagreement in the progress of the study